CliffBio
biologic

CAPVAXIVE

Pneumococcal 21-valent Conjugate Vaccine

Loss of exclusivityJune 2036FDA regulatory exclusivity expiry
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameCAPVAXIVE
Active ingredientPneumococcal 21-valent Conjugate Vaccine
Strength84UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJune 2024
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

CAPVAXIVE patent cliff — loss of exclusivity June 2036 | CliffBio